Uncategorized Archives - Page 14 of 248

TuesdayOct 31, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn

Lexaria, a global innovator in drug delivery platforms, just announced an exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology Lexaria will also perform specific DehydraTECH-related manufacturing operations on SulfoSyn’s behalf for an initial term of 2 years The license agreement adds to Lexaria’s growing list, which, as of the last two years, includes BevNology LLC, Premier Wellness Science Co. Ltd., and Dehydr8, LLC, among others It highlights the superiority of Lexaria’s technology, as further compounded by the 37 patents granted so far Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its latest…

ThursdayOct 26, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors

Lexaria has continuously taken steps to protect its intellectual property internationally to safeguard the applicability of its patented DehydraTECH(TM) technology across the globe The company recently announced that it had received two new Canadian patents, increasing to 37 the number of granted patents in its intellectual property (“IP”) portfolio Lexaria has filed tens of patent applications in multiple jurisdictions that are considered to have the highest commercial potential The company continues to investigate opportunities that could culminate in expansions of and additions to its intellectual property portfolio and is also filing new patent applications for discoveries that arise from its…

ThursdayOct 19, 2023 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Raised $1.6 Million in Latest Investment Round; Looks to Advance DehydraTECH(TM) Research Operations

Lexaria, a global innovator in drug delivery platforms, recently announced that it had entered into a securities purchase agreement with a single health-focused institutional investor The agreement is for the purchase of 1,618,330 shares of common stock at $0.97 per share, with gross proceeds amounting to approximately $1.6 million The raised funds will be integral to Lexaria advancing its operations, inching it closer to FDA approval for its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension It will also help assert Lexaria’s position as a leader in the market, even as it pushes the envelope in terms of research…

MondayOct 16, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs

Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022 Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study These studies follow Lexaria’s announcement of its intention to study weight loss and diabetes control in a human population using DehydraTECH Lexaria Bioscience (NASDAQ: LEXX), a…

FridaySep 29, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application

Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral…

ThursdaySep 21, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Demonstrate DehydraTECH-CBD Benefits in Upcoming Investigational New Drug Application Submission

Lexaria’s IND application builds on five previous human clinical studies showing zero serious adverse effects and evidencing a reduction in resting blood pressure in test subjects DehydraTECH(TM)-CBD has the potential to have pronounced clinical benefits relative to the available anti-hypertensive therapeutics on the market today Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the IND application Lexaria is waiting to submit until the necessary documentation outside of their control is ready for the IND application Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains…

ThursdaySep 21, 2023 4:20 am

420 with CNW — California Lawmakers Send Cannabis Cafe Bill to Governor for Enactment

The California Assembly has approved a bill to legalize marijuana cafes in the state; the body sent the bill to Governor Gavin Newsom’s desk for his signature. Bill AB 374 would allow recreational cannabis dispensaries to provide customers with noncannabis drinks and foods as long as they receive approval from local authorities. Senate lawmakers received the measure from assemblymembers, made slight amendments, and approved it in a 33 to 3 vote nearly one week ago before sending it back to the assembly for a concurrence vote. The assembly voted in favor of the amended cannabis cafe bill just a few…

MondaySep 18, 2023 10:30 am

420 Expo 2023: Celebrating the Cannabis Culture

Cannabis enthusiasts, investors, decision-makers, and business owners, are invited to attend the 420 Expo 2023 to be held in New Jersey Expo Center, Edison, NJ from September 29 – October 1, 2023. The electrifying event is set to blaze the ever-evolving cannabis landscape, including medical experts discussing the therapeutic potential of cannabis and professionals sharing their success stories. 420 Expo 2023 is a one-of-a-kind gathering that celebrates the world of cannabis culture, from its insightful medical applications to its important role in mainstream culture. Featuring the legendary Cheech Marin as a special guest host, the dynamic cannabis convergence promises to…

FridaySep 15, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria’s IND application for its U.S. Phase 1b Hypertension Clinical Study, HYPER-H23-1, remains on track despite setbacks Work mostly under Lexaria’s control was completed earlier this year, while work that is outside its control remains delayed Regardless, Lexaria continues to make progress, even as it looks to take advantage of the growing global cardiovascular drugs market, which is projected to post a CAGR of 3.1% between 2021 and 2026 Chris Bunka, Lexaria’s CEO, has lauded the company’s exceptional discovery, which demonstrates the ability of the patented DehydraTECH-processed CBD to lower blood pressure in the patient population Lexaria Bioscience (NASDAQ: LEXX),…

TuesdaySep 12, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Investigational Research Programs Position the Company for Important Partnership Opportunities and Growth

Lexaria Bioscience has completed several studies that confirm and support the superiority and advantages of its patented DehydraTECH(TM) technology over traditional oral delivery methods The company recently announced results from its human oral nicotine study NIC-H22-1 comparing its DehydraTECH-nicotine pouch to world-leading brands, Zyn(R) and on!(R) Results from the study demonstrated that DehydraTECH-nicotine was statistically significantly faster in reaching Tmax than both brands Lexaria has also undertaken other investigational research programs, including the analysis and execution of hypertension, diabetes, hormone therapy, and dementia studies, which could birth excellent partnership opportunities, supporting further growth A report by Zacks Investment Research discussed…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

Category: Uncategorized